ClinicalTrials.gg
Enrolling by invitationNCT07431437Updated Sep 11, 2026

One-Year Results of GENOSS PCB Real-World Study in Femoropopliteal Artery Disease

An observational study in PTA (Percutaneous Transluminal Angioplasty) and Femoropopliteal Artery Disease, sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Genoss Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
19 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB by enrolling and tracking patients who underwent percutaneous transluminal angioplasty using GENOSS PCB in patients with femoropopliteal artery disease.

Read the detailed description

This prospective, multicenter, single-arm, observational study will enroll patients with femoropopliteal artery disease undergoing PTA with the GENOSS® PCB at 6 hospitals.

Because this is an observational study, the number of participants will not be calculated separately, but a total of 300 participants are planned to be recruited during the study period.

All patients will be followed up at 12 months postprocedure to evaluate the safety and efficacy of the paclitaxel-coated PTA balloon catheter.

02

Conditions studied

  • PTA (Percutaneous Transluminal Angioplasty)
  • Femoropopliteal Artery Disease
03

In context

Lead sponsor

Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patient with percutaneous transluminal angioplasty with GENOSS® PCB in the femoropopliteal artery disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Enrollment in the study was limited to patients who met the following inclusion criteria:

  1. Subject was ≥19 years of age.
  2. Subject had target limb Rutherford classification 2, 3, 4 or 5.
  3. Subject with femoropopliteal artery disease who underwent percutaneous transluminal angioplasty using the GENOSS PCB.
  4. At least one patent native ouflow artery to the ankle of foot, free from significant stenosis (≥50% stenosis) as confirmed by angiography.
  5. Subject provided written and was willing to comply with the study follow-up requirements.

Exclusion criteria

Exclusion Criteria:

Patients were not permitted to enroll in the study if they met any of the following exclusion criteria:

  1. Subjects was allergic to paclitaxel.
  2. Subjects with or to antiplatelet therapy.
  3. Subject had of less than 2 years.
  4. Women who were pregnant, breast-feeding or intended to become pregnant.
  5. Subject was participating in another drug or medical device study.
  6. Subject was unwilling or unable to comply with procedures specified in the protocol or had difficulty or inability to return for follow-up visits as specified by the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • GENOSS® Peripheral DCB PTA Catheter

    Patient treated with GENOSS PCB in the femoropopliteal artery disease

06

What researchers measure

Primary outcomes

  1. The primary safety endpoint

    The primary safety endpoint is the Major Adverse Events (MAEs)-free rate, defined as a composite of freedom from all-cause death through 1month post procedure and/or freedom from both major target limb amputation and/or clinically-driven target lesion revascularization (TLR) through 12months post procedure.

    Time frame: at 12 months post procedure

  2. The primary effectiveness endpoint

    The primary effectiveness endpoint is a primary patency, defined as a composite of freedom from clinically driven target lesion revascularization (CD-TLR) and freedom from binary restenosis (restenosis defined as peak systolic velocity ratio \[PSVR\] ≥ 2.4 assessed by duplex ultrasound or ≥ 50% stenosis as assessed by CT angiography) through 12months post procedure.

    Time frame: at 12 months post procedure

Secondary outcomes

  1. Target lesion revascularization (TLR, %)

    TLR is defined as any re-intervention within the target lesion due to symptoms or drop of ABI/TBI of ≥ 20% or \> 0.15 when compared to post procedure baseline.

    Time frame: at 1 month, 6 months, and 12 months post procedure

  2. Change in Rutherford classification

    Clinical improvement as assessed by changes in target limb Rutherford classification from baseline. Scores on the Rutherford classification range from 0 to 6, with higher scores indicating a worse outcome (more severe peripheral artery disease).

    Time frame: at 1 month, 6 months, and 12 months post procedure

  3. Change in ABI (Ankle-brachial index) (or TBI (Toe-brachial index))

    Change in ABI or TBI from baseline. The ABI is calculated as the ratio of systolic blood pressure at the ankle to that in the arm, and the TBI uses toe systolic pressure. Theoretical values range from 0 to 3.0 (or greater), with higher values up to the normal range indicating a better outcome (improved arterial perfusion). A lower index indicates more severe peripheral artery disease.

    Time frame: at 1 month, 6 months, and 12 months post procedure

  4. Device success rate (%)

    Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)

    Time frame: during the procedure

  5. Procedural success rate (%)

    Procedural success is defined as residual stenosis of ≤ 50% by core laboratory

    Time frame: immediately post procedure

  6. Clinical success rate (%)

    Clinical success is defined as procedural success without complications (i.e. death, major target limb amputation, clinically-driven TLR) during the hospital stay post procedure.

    Time frame: up to 1 week

  7. All-cause death (%)

    Time frame: at 12 months post procedure

  8. Target vessel revascularization (TVR, %)

    Time frame: at 1 month, 6 months, and 12 months post procedure

  9. Major target limb amputation (%)

    Major target limb amputation is defined as any amputation above the ankle on the target limb.

    Time frame: at 12 months post procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Jun 17, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431437
Lead sponsor
Genoss Co., Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Jun 17, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion